Jim Grunwald, Emily Heffernan, New Process Technologies, and Ryan McDonough, DPS Group Global12.19.22
Contract development and manufacturing organizations (CDMOs) continue to benefit from a global surge in the advanced therapy medicinal products (ATMP) market. Consequently, however, CDMOs are also facing long lines of companies in need of their services – wait times for a pharmaceutical company’s place in line can be anywhere from 12 to 18 months or even longer.
To adequately address the demand for their services, CDMOs have begun to design and construct new facilities at unprecedented rates. For those still sitting on the fence as to how to undertake the investment, it’s important to remember that a successful strategy may need to thread the needle with flexible multimodal design rather than strictly dedicated specialization.
Growth statistics
A quick review of statistics – both in terms of demand for new products and the potential size of the CDMO market worldwide – offers an eye-opening reinforcement of the need for outsourcing services that can be applied to a wide range of potential products.
Here in the U.S., the Food and Drug Administration
To adequately address the demand for their services, CDMOs have begun to design and construct new facilities at unprecedented rates. For those still sitting on the fence as to how to undertake the investment, it’s important to remember that a successful strategy may need to thread the needle with flexible multimodal design rather than strictly dedicated specialization.
Growth statistics
A quick review of statistics – both in terms of demand for new products and the potential size of the CDMO market worldwide – offers an eye-opening reinforcement of the need for outsourcing services that can be applied to a wide range of potential products.
Here in the U.S., the Food and Drug Administration
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
